911297-02-4

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 2-fluoro-4-hydroxyphenylcarbamate is utilized as a key intermediate in organic synthesis for the creation of complex organic molecules. Its unique structure allows for versatile chemical reactions, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In pharmaceutical research, tert-butyl 2-fluoro-4-hydroxyphenylcarbamate is employed as a building block for the development of new drugs. Its structural features contribute to the design of molecules with potential pharmacological properties, which can be further optimized for therapeutic applications.
Used in Agrochemical Development:
Tert-butyl 2-fluoro-4-hydroxyphenylcarbamate may also have applications in the development of new agrochemicals, such as pesticides or herbicides, due to its potential pesticidal properties. Its unique chemical structure can be leveraged to create novel agrochemicals that are more effective and environmentally friendly.
Further Research:
While tert-butyl 2-fluoro-4-hydroxyphenylcarbamate shows promise in various applications, further research is necessary to fully understand its potential uses and effects. This includes exploring its pharmacological properties, evaluating its efficacy in drug development, and assessing its environmental impact in agrochemical applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 399-95-1 4-amino-3-fluorophenol 
• 394-41-2 3-fluoro-4-nitrophenol 

Downstream Products

• 1163720-60-2 4-(4-N-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-3-nitro-2-aminopyridine 
• 1217299-24-5 tert-butyl 2-fluoro-4-(2-(methylamino)-3-nitropyridin-4-yloxy)phenylcarbamate 
• 1163720-66-8 4-(4-N-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2,3-diaminopyridine 
• 1160825-89-7 ethyl 4-(4-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2-aminopyridin-3-yl-carbamate 
• 1160825-91-1 ethyl 4-(4-amino-3-fluorophenoxy)-2-aminopyridin-3-yl-carbamate 
• 1160825-93-3 ethyl (4-(4-amino-3-fluorophenoxy)-2-aminopyridin-3-yl)(methyl)carbamate 
• 1160825-67-1 7-(4-amino-3-fluorophenoxy)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one 
• 1321451-78-8 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(1-N-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl)urea 
• 1321451-84-6 1-(3-tert-butyl-1-(3-fluorophenyl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl)urea 
• 1217299-25-6 tert-butyl 4-(3-amino-2-(methylamino)pyridin-4-yloxy)-2-fluorophenylcarbamate 
• 1217299-26-7 tert-butyl 2-fluoro-4-(3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenylcarbamate 
• 1217299-21-2 7-(4-amino-3-fluorophenoxy)-3-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one 
• 1217299-23-4 7-(4-amino-3-fluorophenoxy)-1,3-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one 
• 1163721-04-7 8-(4-amino-3-fluorophenoxy)pyrido[2,3-b]pyrazin-3(4H)-one 

Relevant academic research and scientific papers

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

Preparation method of regrafenib derivatives

The invention discloses a preparation method of regrafenib derivatives. Best reaction steps and reaction conditions are screened out through a lot of experiments, and the method has the advantages ofreasonable design of the whole process, high maneuverabi

1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRID1N-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as "IP compounds"), which, inter alia, are useful in

Novel potent BRAF inhibitors: Toward 1 nM compounds through optimization of the central phenyl ring

BRAF, a serine/threonine specific protein kinase that is part of the MAPK pathway and acts as a downstream effector of RAS, is a potential therapeutic target in melanoma. We have developed a series of small-molecule BRAF inhibitors based on a 1H-imidazo[4,5-b]pyridine-2(3H)-one scaffold (ring A) as the hinge binding moiety and a number of substituted phenyl rings C that interact with the allosteric binding site. The introduction of various groups on the central phenyl ring B combined with appropriate A- and C-ring modifications afford very potent compounds that inhibit V600EBRAF kinase activity in vitro and oncogenic BRAF signaling in melanoma cells. Substitution on the central phenyl ring of a 3-fluoro, a naphthyl, or a 3-thiomethyl group improves activity to yield compounds with an IC50 of 1 nM for purified V 600EBRAF and nanomolar activity in cells.

PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer

A new series of androgen receptor targeted agents (ARTA) was prepared and tested in androgen-dependent and -independent prostate cancer cell lines. These agents were bicalutamide analogs with isothiocyanato substituted B-rings. Also, the linker sulfone of R-bicalutamide was maintained or replaced with several alternative linkages including ether, amine, N-methylamine, thioether, and methylene (in this case the product was a racemic mixture) functional groups at the X-position. To expand the structure-activity relationship (SAR) of these arylisothiocyanato AR ligands, B-ring halogenated arylisothiocyanato ligands were also prepared and tested. The arylisothiocyanato AR ligands showed strong binding affinities to AR ranging from 0.6 to 54 nM. Among them, thioether and ether linkages demonstrated high binding affinities (0.6 and 4.6 nM, respectively) and selective cell growth inhibition (approximately 3- to 6-fold) for LNCaP, an androgen-dependent prostate cancer cell line, when compared to the androgen independent prostate cell lines (DU145, PC-3, and PPC-1) and a bladder cell line (TSU-Pr1). However, the ligands were inactive (IC50>100 mM) in a normal monkey kidney cell line (CV-1) that was used as the control for non-specific toxicity.